Cargando…

Favourable outcome of patients with breast cancer brain metastases treated with dual HER2 blockade of trastuzumab and pertuzumab

BACKGROUND: Dual human epidermal growth factor receptor 2 (HER2) blockade with trastuzumab and pertuzumab (TP) is a standard therapy of metastatic and localized HER2-positive breast cancer (BC), but its activity in breast cancer brain metastases (BCBM) is unknown. METHODS: Patients with HER2-positiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bergen, Elisabeth Sophie, Binter, Amelie, Starzer, Angelika Martina, Heller, Gerwin, Kiesel, Barbara, Tendl-Schulz, Kristina, Bago-Horvath, Zsuzsanna, Furtner, Julia, Leitner, Johannes, Exner, Ruth, Fitzal, Florian, Dieckmann, Karin, Widhalm, Georg, Preusser, Matthias, Berghoff, Anna Sophie, Bartsch, Rupert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072867/ https://www.ncbi.nlm.nih.gov/pubmed/33995593 http://dx.doi.org/10.1177/17588359211009002

Ejemplares similares

Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial
por: Bartsch, Rupert, et al.
Publicado: (2022)

Brain-only metastatic breast cancer is a distinct clinical entity characterised by favourable median overall survival time and a high rate of long-term survivors
por: Berghoff, A S, et al.
Publicado: (2012)

Systemic inflammation scores correlate with survival prognosis in patients with newly diagnosed brain metastases
por: Starzer, Angelika M., et al.
Publicado: (2021)

Primary tumor side is associated with prognosis of colorectal cancer patients with brain metastases
por: Bergen, E.S., et al.
Publicado: (2021)

Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
por: Bianchini, Giampaolo, et al.
Publicado: (2017)

High correlation of temporal muscle thickness with lumbar skeletal muscle cross-sectional area in patients with brain metastases
por: Leitner, Johannes, et al.
Publicado: (2018)

Immune escape mechanisms and therapeutic approaches in cancer: the cancer-immunity cycle
por: Starzer, Angelika M., et al.
Publicado: (2022)

Prognostic factors in adult brainstem glioma: a tertiary care center analysis and review of the literature
por: Leibetseder, Annette, et al.
Publicado: (2021)

Characterization of infections and hypogammaglobulinemia treated with the combination of pertuzumab and trastuzumab
por: Mortimer, Joanne E., et al.
Publicado: (2019)

Ovarian cancer with high-level focal ERBB2 amplification responds to trastuzumab and pertuzumab
por: Thouvenin, Laure, et al.
Publicado: (2021)

LAG-3 expression in the inflammatory microenvironment of glioma
por: Mair, Maximilian J., et al.
Publicado: (2021)

Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers
por: Berghoff, Anna S, et al.
Publicado: (2016)

Skin/nail infections with the addition of pertuzumab to trastuzumab-based chemotherapy
por: Mortimer, Joanne, et al.
Publicado: (2014)

Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex
por: Hao, Yue, et al.
Publicado: (2019)

BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer
por: Dang, Chau, et al.
Publicado: (2022)

Perioperative imaging in patients treated with resection of brain metastases: a survey by the European Association of Neuro-Oncology (EANO) Youngsters committee
por: Kiesel, Barbara, et al.
Publicado: (2020)

Pertuzumab Increases 17-AAG-Induced Degradation of ErbB2, and This Effect Is Further Increased by Combining Pertuzumab with Trastuzumab
por: Hughes, Juliana Bentes, et al.
Publicado: (2012)

Temporal muscle thickness is an independent prognostic marker in melanoma patients with newly diagnosed brain metastases
por: Furtner, Julia, et al.
Publicado: (2018)

Pertuzumab and Trastuzumab Combination with Concomitant Locoregional Radiotherapy for the Treatment of Breast Cancers with HER2 Receptor Overexpression
por: Aboudaram, Amélie, et al.
Publicado: (2021)

Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer
por: Sims, A H, et al.
Publicado: (2012)

In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma
por: El-Sahwi, K, et al.
Publicado: (2010)

The Effects of Pertuzumab and Its Combination with Trastuzumab on HER2 Homodimerization and Phosphorylation
por: Nami, Babak, et al.
Publicado: (2019)

Correction: Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex
por: Hao, Yue, et al.
Publicado: (2019)

Trastuzumab Associated With Recurrent Severe Thrombocytopenia and Successful Use of Pertuzumab Monotherapy
por: Huff, Mallorie L, et al.
Publicado: (2022)

Pruritus Related to Trastuzumab and Pertuzumab in HER2+ Breast Cancer Patients
por: Gu, Stephanie, et al.
Publicado: (2023)

Survival prediction using temporal muscle thickness measurements on cranial magnetic resonance images in patients with newly diagnosed brain metastases
por: Furtner, Julia, et al.
Publicado: (2017)

Prognostic impact of breast cancer subtypes in elderly patients
por: Bergen, E. S., et al.
Publicado: (2016)

Brain metastases as first manifestation of advanced cancer: exploratory analysis of 459 patients at a tertiary care center
por: Füreder, L. M., et al.
Publicado: (2018)

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
por: Veeraraghavan, Jamunarani, et al.
Publicado: (2021)

Clinical characteristics, treatment, and long-term outcome of patients with brain metastases from thyroid cancer
por: Wolff, Ladislaia, et al.
Publicado: (2023)

Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2(+) breast cancer in the adaptively randomized I-SPY2 trial
por: Clark, Amy S., et al.
Publicado: (2021)

Binding Affinity of Trastuzumab and Pertuzumab Monoclonal Antibodies to Extracellular HER2 Domain †
por: Cruz, Victor L., et al.
Publicado: (2023)

Sarcopenia in Neurological Patients: Standard Values for Temporal Muscle Thickness and Muscle Strength Evaluation
por: Steindl, Ariane, et al.
Publicado: (2020)

Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation
por: Yamashita-Kashima, Yoriko, et al.
Publicado: (2020)

Comparative Effectiveness and Safety of Pertuzumab and Trastuzumab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy for Treatment of Metastatic Breast Cancer
por: Dai, Wei Fang, et al.
Publicado: (2022)

Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma
por: Mair, Maximilian J., et al.
Publicado: (2021)

Brain metastases from hepatopancreatobiliary malignancies
por: Bergen, Elisabeth S., et al.
Publicado: (2023)

Enrichment and Liquid Chromatography–Mass Spectrometry Analysis of Trastuzumab and Pertuzumab Using Affimer Reagents
por: Olaleye, Oladapo, et al.
Publicado: (2021)

Pertuzumab in Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment for HER2-Positive Breast Cancer
por: Vieira, Cláudia, et al.
Publicado: (2022)

Noninvasive Differentiation of Meningiomas and Dural Metastases Using Intratumoral Vascularity Obtained by Arterial Spin Labeling
por: Furtner, Julia, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_co4gdsnui928kufdp9jheikndb